pyrroles has been researched along with bezafibrate in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 16 (76.19) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adzet, T; Alegret, M; Díaz, C; Hernández, G; Laguna, JC; Sánchez, RM; Verd, JC | 1 |
| de Man, FH; Mohrschladt, MF; Smelt, AH; Stoeken, DJ; Sturk, A; Westendorp, RG; Weverling-Rijnsburger, AW | 1 |
| Adzet, T; Alegret, M; Cabrero, A; Laguna, JC; Sánchez, RM; Vázquez, M | 1 |
| Black, DM | 1 |
| Arístegui, R; Canudas, J; Cenarro, A; Civeira, F; Díaz, C; Garcí-Otín, AL; Hernández, G; Masramon, X; Pocoví, M; Sol, JM | 1 |
| Hiyoshi, H; Ikuta, H; Ito, M; Kurusu, N; Okada, T; Saeki, T; Shinmyo, D; Tanaka, H; Tanaka, K; Yanagimachi, M; Yoshida, I | 1 |
| Aristegui, R; Chaves, J; Civeira, F; da Silva, PM; Díaz, C; Gómez-Gerique, JA; Hernández, A; Hernández, G; Lima, J; Mostaza, JM; Oliván, J; Pintó, X; Rodriguez-Botaro, A; Ros, E; Sol, JM; Vilardell, M; Zambón, D | 1 |
| Aristegui, R; Civeira, F; Díaz, C; García-Otín, AL; Hernández, G; Masramon, X; Pocoví, M; Recalde, D; Sol, JM | 1 |
| Backes, JM; Moriarty, PM | 1 |
| Blanco-Colio, LM; Díaz, C; Egido, J; Hernández, G; Martín-Ventura, JL; Sol, JM | 1 |
| Bulut, D; Bulut-Streich, N; Graf, C; Hanefeld, C; Mügge, A; Spiecker, M | 1 |
| Fujioka, D; Ichigi, Y; Kawabata, K; Kitta, Y; Kodama, Y; Kugiyama, K; Mende, A; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Umetani, K | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Arístegui, R; Artieda, M; Cenarro, A; Civeira, F; Díaz, C; Gañán, A; Gonzalvo, C; Meriño-Ibarra, E; Pocoví, M; Sol, JM | 1 |
| Fujioka, D; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Mende, A; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Umetani, K | 1 |
| Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM | 1 |
| Avisar, I; Brook, JG; Wolfovitz, E | 1 |
| Inazu, A; Kawashiri, MA; Kobayashi, J; Mabuchi, H; Nakanishi, C; Noguchi, T; Nohara, A; Tada, H; Yamagishi, M | 1 |
| Hohendorff, B; Mühldorfer-Fodor, M; Prommersberger, KJ; Schmitt, R; Wagner, M | 1 |
| Gong, HR; Huang, WY; Huang, XS; Li, XP; Zhao, SP | 1 |
| Gong, HR; Huang, WY; Li, XP; Zhao, SP | 1 |
2 review(s) available for pyrroles and bezafibrate
| Article | Year |
|---|---|
Statins in children: what do we know and what do we need to do?
Topics: Atorvastatin; Bezafibrate; Child; Child Welfare; Cost-Benefit Analysis; Drug Approval; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States | 2006 |
12 trial(s) available for pyrroles and bezafibrate
| Article | Year |
|---|---|
Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Cross-Over Studies; Cytokines; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Reference Values | 2000 |
Chitotriosidase genotype and serum activity in subjects with combined hyperlipidemia: effect of the lipid-lowering agents, atorvastatin and bezafibrate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Bezafibrate; DNA; Double-Blind Method; Exons; Female; Genotype; Heptanoic Acids; Hexosaminidases; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged; Polymorphism, Genetic; Pyrroles | 2001 |
Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia.
Topics: Adult; Atorvastatin; Bezafibrate; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides | 2002 |
Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Bezafibrate; Cholesterol; DNA; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Middle Aged; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Triglycerides | 2002 |
Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin.
Topics: Adult; Antineoplastic Agents; Atorvastatin; Bezafibrate; Biomarkers; Carotid Artery Diseases; Carotid Artery, Common; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Endothelial Cells; Fas Ligand Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Membrane Glycoproteins; Mevalonic Acid; Middle Aged; Pyrroles; Terpenes; Time Factors; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha | 2004 |
Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Biomarkers; Cholesterol; Coronary Artery Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Triglycerides; Vasodilation | 2005 |
Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
Topics: Adult; Aged; Atorvastatin; Bezafibrate; Cytosine; Female; Genetic Variation; Genotype; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipase; Lipids; Lipoproteins; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Pyrroles; Reference Values; Thymine | 2005 |
Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia.
Topics: Adiponectin; Aged; Atorvastatin; Bezafibrate; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2007 |
Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
Topics: Aged; Atorvastatin; Bezafibrate; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides | 2008 |
Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.
Topics: Aged; Apolipoprotein E2; Apolipoprotein E3; Atorvastatin; Bezafibrate; Chromatography, High Pressure Liquid; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Phenotype; Pyrroles | 2011 |
The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Apolipoprotein A-V; Apolipoproteins A; Atorvastatin; Bezafibrate; Cholesterol, HDL; Drug Synergism; Drug Therapy, Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2013 |
[The lipid-regulating effect and safety of combined statin and bezafibrate therapy in acute coronary syndrome patients complicating with dyslipidemia].
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Treatment Outcome | 2013 |
7 other study(ies) available for pyrroles and bezafibrate
| Article | Year |
|---|---|
Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits.
Topics: Acyltransferases; Animals; Atorvastatin; Bezafibrate; Cholesterol; Diacylglycerol O-Acyltransferase; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Lipids; Liver; Male; Phospholipids; Pyrroles; Rabbits; Simvastatin; Triglycerides | 1998 |
Down-regulation of uncoupling protein-3 and -2 by thiazolidinediones in C2C12 myotubes.
Topics: Acyl-CoA Dehydrogenase; Animals; Atorvastatin; Bezafibrate; Carnitine O-Palmitoyltransferase; Carrier Proteins; Cell Line; Cholesterol; Chromans; Down-Regulation; Fatty Acid Desaturases; Heptanoic Acids; Hypoglycemic Agents; Ion Channels; Ligands; Membrane Transport Proteins; Mice; Mitochondrial Proteins; Muscles; Oleic Acid; Peroxisome Proliferators; Proteins; Pyrimidines; Pyrroles; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Triazenes; Troglitazone; Uncoupling Protein 2; Uncoupling Protein 3 | 2000 |
Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism.
Topics: Animals; Atorvastatin; Bezafibrate; Cholesterol; Diphosphonates; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Hepatocytes; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Lipids; Macaca mulatta; Molecular Structure; Pyrroles; Rabbits; Receptors, LDL; Triglycerides | 2001 |
Re: Gómez-Gerique, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 2002;162:245-51.
Topics: Atorvastatin; Bezafibrate; C-Reactive Protein; Drug Interactions; Estrogen Replacement Therapy; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Pyrroles | 2003 |
Comparison of endothelial function in patients with metabolic syndrome on bezafibrate or atorvastatin therapy.
Topics: Aged; Atorvastatin; Bezafibrate; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Coronary Circulation; Endothelium, Vascular; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Regional Blood Flow; Treatment Outcome; Vasodilation | 2005 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
[Focal myositis as a side effect of antilipidemics - 2 patients with involvement of the forearm].
Topics: Anticholesteremic Agents; Atorvastatin; Bezafibrate; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Forearm; Heptanoic Acids; Humans; Hyperlipidemias; Image Interpretation, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Myositis; Pyrroles | 2012 |